| 14.28 -3.57 (-20%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.69 |
1-year : | 21.8 |
| Resists | First : | 16.86 |
Second : | 18.67 |
| Pivot price | 16.94 |
|||
| Supports | First : | 13.93 |
Second : | 11.59 |
| MAs | MA(5) : | 17 |
MA(20) : | 17.12 |
| MA(100) : | 13.75  |
MA(250) : | 13.5 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 55.6 |
D(3) : | 69 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 18.92 | Low : | 9.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NVCR ] has closed below the lower bollinger band by 20.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 2.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.12 - 15.19 | 15.19 - 15.26 |
| Low: | 13.74 - 13.82 | 13.82 - 13.91 |
| Close: | 14.12 - 14.26 | 14.26 - 14.4 |
NovoCure Limited operates as an oncology enterprise specializing in the development, manufacturing, and global commercialization of its proprietary Tumor Treating Fields (TTFields) technology. These innovative devices are engineered to treat solid tumor cancers, with the company's market presence spanning the United States, Europe, the Middle East, Africa, Japan, and Greater China. The company's commercialized offerings include Optune, which is indicated for glioblastoma, and Optune Lua, approved for use in malignant pleural mesothelioma. Beyond these established treatments, NovoCure actively conducts, or has completed, clinical research into the potential applications of TTFields for a broader spectrum of cancers. These investigational areas encompass brain metastases, gastric cancer, further studies in glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. Founded in 2000, NovoCure Limited is headquartered in Saint Helier, Jersey.
Thu, 18 Jun 2026
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) - PR Newswire
Thu, 18 Jun 2026
NovoCure (NVCR) Stock Could Be 31.5% Undervalued After TRIDENT Trial Result - simplywall.st
Thu, 18 Jun 2026
Novocure (NVCR) Experiences Significant Decline in Stock Price - GuruFocus
Thu, 18 Jun 2026
Novocure TRIDENT trial misses primary endpoint - grafa.com
Thu, 18 Jun 2026
Novocure (NVCR) Sees Significant Decline in Stock Price - GuruFocus
Thu, 18 Jun 2026
Novocure Brain Cancer Study Shows No Significant Survival Benefit, Stock Tanks - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 116 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 10 (%) |
| Held by Institutions | 88.4 (%) |
| Shares Short | 9,150 (K) |
| Shares Short P.Month | 6,970 (K) |
| EPS | -1.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.85 |
| Profit Margin | -25.7 % |
| Operating Margin | -38.8 % |
| Return on Assets (ttm) | -11.1 % |
| Return on Equity (ttm) | -50 % |
| Qtrly Rev. Growth | 12.3 % |
| Gross Profit (p.s.) | 4.39 |
| Sales Per Share | 5.82 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | -9.34 |
| PEG Ratio | 0 |
| Price to Book value | 4.99 |
| Price to Sales | 2.45 |
| Price to Cash Flow | -61.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|